BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 31213774)

  • 1. Efficacy and toxicity of cladribine for the treatment of refractory acute myeloid leukemia: a meta-analysis.
    Zhou A; Han Q; Song H; Zi J; Ma J; Ge Z
    Drug Des Devel Ther; 2019; 13():1867-1878. PubMed ID: 31213774
    [No Abstract]   [Full Text] [Related]  

  • 2. Cladribine with Granulocyte Colony-Stimulating Factor, Cytarabine, and Aclarubicin Regimen in Refractory/Relapsed Acute Myeloid Leukemia: A Phase II Multicenter Study.
    Wang H; Wang L; Li C; Wuxiao Z; Shao R; Wang H; Lu Y
    Oncologist; 2020 Nov; 25(11):e1663-e1670. PubMed ID: 32845551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cladribine, cytarabine, and filgrastim based regimen in relapsed or refractory acute myeloid leukemia: A systematic review and meta-analysis.
    Cao S; Tao Q; Wang J; Zhang Q; Dong Y
    Medicine (Baltimore); 2023 Nov; 102(44):e34949. PubMed ID: 37933074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of cladribine addition to induction treatment of newly diagnosed acute myeloid leukemia: a systematic review and meta-analysis.
    Pan Q; Li J
    Hematology; 2021 Dec; 26(1):577-587. PubMed ID: 34384339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multicenter, open, non-comparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, and G-CSF as induction therapy in refractory acute myeloid leukemia - a report of the Polish Adult Leukemia Group (PALG).
    Wrzesień-Kuś A; Robak T; Lech-Marańda E; Wierzbowska A; Dmoszyńska A; Kowal M; Hołowiecki J; Kyrcz-Krzemień S; Grosicki S; Maj S; Hellmann A; Skotnicki A; Jedrzejczak W; Kuliczkowski K;
    Eur J Haematol; 2003 Sep; 71(3):155-62. PubMed ID: 12930315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of common salvage chemotherapy regimens in patients with refractory or relapsed acute myeloid leukemia: A retrospective cohort study.
    Xu J; Lv TT; Zhou XF; Huang Y; Liu DD; Yuan GL
    Medicine (Baltimore); 2018 Sep; 97(39):e12102. PubMed ID: 30278488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Efficacy and safety analysis of the combination of cladribine, cytarabine, granulocyte colonystimulating factor (CLAG) regime in patients with refractory or relapsed acute myeloid leukemia].
    Duan MH; Zhang Y; Zhang M; Han X; Zhang Y; Yang C; Feng J; Zhang L; Zhang W; Li J; Tian LP; Zhang Y; Zhou DB
    Zhonghua Xue Ye Xue Za Zhi; 2016 Jul; 37(7):571-5. PubMed ID: 27535856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute myeloid leukemia induction with cladribine: Outcomes by age and leukemia risk.
    Schoen MW; Woelich SK; Braun JT; Reddy DV; Fesler MJ; Petruska PJ; Freter CE; Lionberger JM
    Leuk Res; 2018 May; 68():72-78. PubMed ID: 29574395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of Efficacy and Prognostic Factors of CLAG Treatment in Chinese Patients with Refractory or Relapsed Acute Myeloid Leukemia.
    Wang L; Xu J; Tian X; Lv T; Yuan G
    Acta Haematol; 2019; 141(1):43-53. PubMed ID: 30517910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effectiveness of CLAT Protocol for Treating Patients with Refractory Acute Myeloid Leukemia].
    Chen XM; Weng JY; Deng CX; Wang YL; Chao Z; Lai PL; Li MM; Liao PJ; Huang X; Ling W; Wan CC; Wu SJ; Zhong LY; Lu ZS; Zou XL; DU X
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Apr; 24(2):399-404. PubMed ID: 27150999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Revisiting the role of cladribine in acute myeloid leukemia: an improvement on past accomplishments or more old news?
    Freyer CW; Gupta N; Wetzler M; Wang ES
    Am J Hematol; 2015 Jan; 90(1):62-72. PubMed ID: 25284482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial.
    Kadia TM; Cortes J; Ravandi F; Jabbour E; Konopleva M; Benton CB; Burger J; Sasaki K; Borthakur G; DiNardo CD; Pemmaraju N; Daver N; Ferrajoli A; Wang X; Patel K; Jorgensen JL; Wang S; O'Brien S; Pierce S; Tuttle C; Estrov Z; Verstovsek S; Garcia-Manero G; Kantarjian H
    Lancet Haematol; 2018 Sep; 5(9):e411-e421. PubMed ID: 30115541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cladribine in the remission induction of adult acute myeloid leukemia: where do we stand?
    Qasrawi A; Bahaj W; Qasrawi L; Abughanimeh O; Foxworth J; Gaur R
    Ann Hematol; 2019 Mar; 98(3):561-579. PubMed ID: 30470874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [CLAG Regimen Composed of Continuous Intravenous Infusion of Cladribine in the Treatment of Refractory/Relapsed Acute Myeloid Leukemia].
    Mi RH; Chen L; Yang HP; Wang XJ; Guo SL; Shi L; Yin QS; Wei XD
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Apr; 29(2):333-338. PubMed ID: 33812396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Homoharringtonine combined with cladribine and aclarubicin (HCA) in acute myeloid leukemia: A new regimen of conventional drugs and its mechanism.
    Wang F; Xie M; Chen P; Wang D; Yang M
    Oxid Med Cell Longev; 2022; 2022():8212286. PubMed ID: 35873796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of cladribine- and fludarabine-based induction chemotherapy in relapsed or refractory acute myeloid leukaemia.
    Park H; Youk J; Kim I; Yoon SS; Park S; Lee JO; Bang SM; Koh Y
    Ann Hematol; 2016 Oct; 95(11):1777-86. PubMed ID: 27539617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Re-induction with modified CLAG regimen in relapsed or refractory acute myeloid leukemia in children bridging to allogeneic hematopoietic stem cell transplantation.
    Zhang N; Shao JB; Li H; Yang JW; Chen K; Zhu JS; Jiang H
    World J Pediatr; 2020 Apr; 16(2):152-158. PubMed ID: 31748985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukemia Group.
    Wierzbowska A; Robak T; Pluta A; Wawrzyniak E; Cebula B; Hołowiecki J; Kyrcz-Krzemień S; Grosicki S; Giebel S; Skotnicki AB; Piatkowska-Jakubas B; Kuliczkowski K; Kiełbiński M; Zawilska K; Kłoczko J; Wrzesień-Kuś A;
    Eur J Haematol; 2008 Feb; 80(2):115-26. PubMed ID: 18076637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cladribine in the treatment of acute myeloid leukemia: a single-institution experience.
    Martin MG; Welch JS; Augustin K; Hladnik L; DiPersio JF; Abboud CN
    Clin Lymphoma Myeloma; 2009 Aug; 9(4):298-301. PubMed ID: 19717379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modified cladribine, cytarabine, and G-CSF as a salvage regimen in patients with relapsed/refractory acute myeloid leukemia: a bridge to myeloablative allogeneic hematopoietic stem cell transplantation.
    Ye P; Pei R; Jin J; Sun J; Li K; Cao J; Zhou D; Lu Y
    Ann Hematol; 2019 Sep; 98(9):2073-2080. PubMed ID: 31201514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.